2023
Comparing Patient-Reported Outcomes Among Anti-TNF-Experienced Patients with Crohn’s Disease Initiating Vedolizumab Versus Ustekinumab
Kappelman M, Lewis J, Zhang X, Lin F, Weisbein L, Chen W, Burris J, Dorand J, Parlett L, Haynes K, Nair V, Kaul A, Dobes A, Long M. Comparing Patient-Reported Outcomes Among Anti-TNF-Experienced Patients with Crohn’s Disease Initiating Vedolizumab Versus Ustekinumab. Digestive Diseases And Sciences 2023, 68: 3413-3420. PMID: 37115362, DOI: 10.1007/s10620-023-07942-0.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesCohort StudiesCrohn DiseaseHumansProspective StudiesRetrospective StudiesTreatment OutcomeTumor Necrosis Factor InhibitorsUstekinumabConceptsShort Crohn's Disease Activity IndexDisease activity indexCrohn's diseasePain interferenceCorticosteroid useTreatment persistenceSecondary outcomesAnti-tumor necrosis factor therapyOutcomes Measurement Information System (PROMIS) domainsCrohn's Disease Activity IndexEffectiveness of vedolizumabHigher corticosteroid useLower treatment persistenceNecrosis factor therapyCo-primary outcomesPatient-reported outcomesInternet-based cohort studyLogistic regression modelsIBD PartnersCohort studyExperienced patientsFactor therapyPrimary outcomeBiological therapySteroid use
2022
Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease
Kappelman M, Adimadhyam S, Hou L, Wolfe A, Smith S, Simon A, Moyneur É, Reynolds J, Toh S, Dobes A, Parlett L, Haynes K, Selvan M, Ma Q, Nair V, Burris J, Dorand J, Dawwas G, Lewis J, Long M. Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease. The American Journal Of Gastroenterology 2022, 118: 674-684. PMID: 36508681, DOI: 10.14309/ajg.0000000000002068.Peer-Reviewed Original ResearchMeSH KeywordsCrohn DiseaseHumansNecrosisRetrospective StudiesTreatment OutcomeTumor Necrosis Factor InhibitorsUstekinumabConceptsCrohn's diseaseCause hospitalizationCD hospitalizationsTreatment persistenceSecondary outcomesAntitumor necrosis factor therapyReal-world comparative effectiveness studiesAntitumor necrosis factorLarge US insurerNecrosis factor therapyTreatment persistence ratesAnti-TNF treatmentBaseline clinical characteristicsRetrospective cohort studyComparative effectiveness studiesRoute of administrationDiverse US populationLongitudinal claims dataRefractory populationClinical characteristicsCohort studyFactor therapyPrimary outcomePatient preferencesNecrosis factor